NCT06570473View on ClinicalTrials.gov

Feasibility Trial for a Right Ventricular Failure Platform Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pulmonary HypertensionRight Ventricular DysfunctionRight Heart Failure
Interventions
DRUG

Empagliflozin

Tablet

DRUG

Ranolazine

Tablet

Trial Locations (5)

T1Y 6J4

NOT_YET_RECRUITING

University of Calgary, Calgary

T6G 2G3

RECRUITING

University of Alberta, Edmonton

V5Z 1M9

NOT_YET_RECRUITING

The University of British Columbia, Vancouver

N6A 5A5

NOT_YET_RECRUITING

London Health Sciences Centre - University Hospital, London

K1Y 4E9

NOT_YET_RECRUITING

The Ottawa Hospital, Ottawa

All Listed Sponsors
collaborator

Canadian Heart Function Alliance

UNKNOWN

collaborator

Accelerating Clinical Trials Consortium

OTHER

collaborator

Ottawa Heart Institute Research Corporation

OTHER

collaborator

Team PHenomenal Hope

UNKNOWN

lead

University of Alberta

OTHER